StockRing: 11/15/09, (NASDAQ:CELG), $53.48, "HOLD" Celgene Corporati (CELG) Stock on Sunday, November 15, 2009

Login    About Us    Our Blog    Our Twitter    Contact Us     11/15/09, (NASDAQ:CELG), $53.48, "HOLD" Celgene Corporati (CELG) Stock  CELG opened at $53.53 and it is $-0.25, (-0.47%). Today's trading range is $53.08 - 54.06. 1y target price is $64.80.  DOW     +0.72%    +73.00    10270.47           ENGLAND     +0.38%    +19.88    5296.38           JAPAN     -0.35%    -34.18    9770.31  NASDAQ     +0.88%    +18.86    2167.88           GERMANY     +0.40%    +22.87    5686.83           CHINA     +0.46%    +14.7    3187.647  S&P 500     +0.57%    +6.24    1093.48           FRANCE     -0.05%    -2.06    3806.01           INDIA     +0.92%    +152.8    16848.83  CANADA     +0.41%    +46.92    11407.68           ITALY     -1.09%    -174.00    15743.00           RUSSIA     -0.41%    -5.85    1419.49  MEXICO     +0.79%    +242.24    31002.090           SWISS     -0.07%    -4.68    6351.08           TAIWAN     -0.07%    -5.3    7665.63

Stocks Funds SYMBOL:    YouTube Our Blog 11/11/09 StockRing Urgent Advice: Buy stocks on 11/12/09 - expect gains this week !!!    Option Exp: SAMPLE ! Option Exp:    EUROs for $1 DOLLAR: 3 MONTHS       Receive FRESH Daily Updates for 17 StockRing Reports for $30/month !!! 1. Dow Jones Index - 30 Stocks on 11/12/2009:  Buy   93% or 28   Hold   7% or 2   Sell   0% or 0 stocks     2. World Markets - 72 Indexes on 11/11/2009:  Buy   63% or 44   Hold   21% or 15   Sell   16% or 11 indexes 3. Best Brands - 200 stocks on 11/12/2009:  Buy   76% or 152   Hold   17% or 33   Sell   7% or 14 stocks 4. Hot News - 200 stocks on 11/8/2009:  Buy   47% or 93   Hold   23% or 46   Sell   30% or 60 stocks 5. Big Movers - 200 stocks on 11/14/2009:  Buy   69% or 137   Hold   23% or 47   Sell   8% or 15 stocks 6. Top Hitters - 200 stocks on 11/11/2009:  Buy   77% or 153   Hold   15% or 31   Sell   8% or 15 stocks 7. S&P 500 Index - 500 Stocks on 7/21/2009:   Buy   68% or 341   Hold   21% or 106   Sell   11% or 53 stocks 8. S&P 400 Mid Cap - 400 Stocks on 7/21/2009:  Buy   73% or 292   Hold   15% or 61   Sell   12% or 47 stocks 9. S&P 600 Small Cap - 600 Stocks on 4/18/2009:  Buy   66% or 395   Hold   26% or 156   Sell   8% or 49 stocks 10. Nasdaq Telecom - 164 Stocks on 7/24/2009:  Buy   49% or 81   Hold   35% or 56   Sell   16% or 27 stocks 11. Nasdaq Computer - 440 Stocks on 7/22/2009:  Buy   60% or 263   Hold   26% or 115   Sell   14% or 62 stocks 12. Nasdaq Finance - 180 Stocks on 7/24/2009:  Buy   61% or 109   Hold   6% or 12   Sell   33% or 59 stocks 13. NYSE International - 100 Stocks on 7/21/2009:  Buy   58% or 58   Hold   34% or 34   Sell   8% or 8 stocks 14. Legg Mason Mutual - 346 Funds on 10/6/2009:  Buy   38% or 133   Hold   51% or 176   Sell   11% or 37 funds 15. T. Row Price Mutual - 161 Funds on 10/6/2009:  Buy   52% or 84   Hold   46% or 73   Sell   2% or 4 funds 16. London FTSE 100 - 94 Stocks on 4/1/2009:  Buy   20% or 19   Hold   50% or 47   Sell   30% or 28 stocks 17. Canada Toronto - 209 Stocks on 4/18/2009:  Buy   53% or 111   Hold   34% or 70   Sell   13% or 28 stocks                                              TOTAL RATINGS:   Buy   60% or 2493   Hold   27% or 1080   Sell   13% or 517 stocks Video: 6-24-09 - Dow 30 stocks Buy-Sell-Hold Ratings 11/15/2009  Sunday, November 15, 2009 (Irvine, California) Today StockRing.com Recommendation is to "HOLD"for Celgene Corporati (NASDAQ:CELG) Stock. CELG stock opening price was $53.53 per share. Current price of NASDAQ:CELG Stock is $53.48 per share and it is $-0.25, (-0.47%) today and it was trading in the daily range of $53.08 - 54.06 per share. Current Bid Price for (NASDAQ:CELG) stock is $52.74 and the Ask Price is $53.57. In the last 52 weeks CELG stock was trading in the range of $36.90 - 61.77. 50-Day Moving Average for (NASDAQ:CELG) stock is $53.8419 and 200-Day Moving Average is $49.4992. On average analysts predict that One Year Target Estimated price for (NASDAQ:CELG) stock is $64.80. Celgene Corporati (NASDAQ:CELG) Market capitalization is $24.580B. (NASDAQ:CELG) stock average daily volume is 3,353,310 shares per day. However, on last trading session of Nov 13, 2009 CELG stock traded 1,751,566 shares. Also The Short Ratio for (NASDAQ:CELG) stock is 1.80. On previous trading session CELG Stock closed at $53.73 per share. Last year Celgene Corporati (NASDAQ:CELG) before taxes (EBITDA) (ttm) earned $573.3M on total revenue of $2.557B. Earnings Per Share - EPS (ttm) for CELG stock is 0.802. Also, (NASDAQ:CELG) Stock Price Per Earnings ratio - P/E is 67.00. Thus, (NASDAQ:CELG) Stock Price/Sales (ttm) ratio is 9.66 and Price/Book (mrq) ratio is 6.00. (NASDAQ:CELG) Stock does NOT PAY any dividend. So at this time (NASDAQ:CELG) Stock maintains Trailing Annual Dividend Rate at 0.00 . StockRing Recommendations for Celgene Corporati (NASDAQ:CELG) Stock are updated daily here http://www.StockRing.com/sr/StockDetail.asp?StockName=CELG If you would like to receive Buy-Sell-Hold ratings for over 50,000 stocks, mutual funds, and ETFs go to StockRing web site: http://www.StockRing.com. CELG Stock Charts:   1d   5d   3m   6m   1y   2y   5y   Max   News    Options!   More Info 11/15/2009 1 Year Stock market price chart for Celgene Corporati (NASDAQ:CELG) Stock on Sunday, November 15, 2009    1 Year Dow Jones Chart 1 Year S&P 500 Chart 1 Year Nasdaq Chart 1 Year Canada Chart 11/15/2009 5 days Stock market price chart for Celgene Corporati (NASDAQ:CELG) Stock on Sunday, November 15, 2009    5 Days Dow Jones Chart 5 Days S&P 500 Chart 5 Days Nasdaq Chart 5 Days Canada Chart CELG Stock Charts:   1d   5d   3m   6m   1y   2y   5y   Max   News    Options!   More Info 11/15/2009 Stock market price quote data for Celgene Corporati (NASDAQ:CELG) Stock on Sunday, November 15, 2009 Last Trade: 53.48 Trade Time: Nov 13 Change: -0.25, (-0.47%) Prev Close: 53.73 Open: 53.53 Bid: 52.74 Ask: 53.57 1y Target Est: $64.80 50-Day Moving Average: 53.8419 200-Day Moving Average: 49.4992 Short Ratio: 1.80 Trailing Annual Dividend Rate: 0.00 Day's Range: 53.08 - 54.06 52wk Range: 36.90 - 61.77 Volume: 1,751,566 Avg Vol: 3,353,310 Market Cap: 24.580B P/E (ttm): 67.00 EPS (ttm): 0.802 Div & Yield: 0.00 (N/A%) Revenue (ttm): 2.557B Earnings before Tax (EBITDA) (ttm): 573.3M Price/Sales (ttm): 9.66 Price/Book (mrq): 6.00 Receive FRESH Daily Updates for 17 StockRing Reports for $30/month !!!    EUROs for $1 DOLLAR: 3 MONTHS       Celgene Corporation (NasdaqGS: CELG) Company Information Celgene Corporation 86 Morris Avenue Summit, NJ 07901 United States - Map Phone: 908-673-9000 Web Site: http://www.celgene.com Celgene Corporation (NasdaqGS: CELG) DETAILS Celgene Corporation (NasdaqGS: CELG) Index Membership: S&P 500 S&P 1500 Super Comp Nasdaq 100 Celgene Corporation (NasdaqGS: CELG) Sector: Healthcare Celgene Corporation (NasdaqGS: CELG) Industry: Biotechnology Celgene Corporation (NasdaqGS: CELG) Full Time Employees: 2,441 Celgene Corporation (NasdaqGS: CELG) BUSINESS SUMMARY Celgene Corporation engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases primarily in Europe and the United States. Its primary commercial stage products include REVLIMID for the treatment in combination with dexamethasone for multiple myeloma patients, as well as for the treatment of patients with transfusion-dependent anemia; and THALOMID for the treatment in combination with dexamethasone of patients with newly diagnosed multiple myeloma, as well as for the treatment and suppression of cutaneous manifestations of erythema nodosum leprosum. The company also sells ALKERAN for the palliative treatment of multiple myeloma and of carcinoma of the ovary; VIDAZA, which is used for the treatment of various subtypes of MDS; RITALIN that is used for the treatment of attention deficit hyperactivity disorder; and FOCALIN for the treatment of oncology-related disorders. Its development stage products consist of CC-4047, which is in Phase II trials for the treatment of myelofibrosis and multiple myeloma, and in Phase I trials for the treatment of hemoglobinopathies; CC-10015 that is in pre-clinical stage for the treatment of inflammatory diseases; CC-10004, which is in Phase II clinical trials for the treatment of psoriasis, psoriatic arthritis, and inflammatory diseases; JNK CC-930 that is in Phase I trial to treat fibrotic diseases; Amrubicin, which is in Phase III trials for small cell lung cancer treatment; Human umbilical cord blood, a Phase I trials product to treat transplants and hematological disorders; and ACE-011, a Phase II initiated product for multiple myeloma/Bone loss treatment. Celgene Corporation has strategic collaborations with Acceleron Pharma, Inc. for the joint development and commercialization of ACE-011; and GlobeImmune Inc. to develop molecular immunotherapy for the treatment of cancer. The company was founded in 1980 and is headquartered in Summit, New Jersey. Celgene Corporation (NasdaqGS: CELG) KEY EXECUTIVES, SALARIES and BONUSES Dr. Sol J. Barer Ph.D., Age: 62 Exec. Chairman, Chief Exec. Officer and Chairman of Exec. Committee Salary: $ 3.11M Bonus: $ 55.97M Mr. Robert J. Hugin MBA, Age: 54 Pres, Chief Operating Officer, Sec. Salary: $ 2.31M Bonus: $ 72.15M Mr. David W. Gryska , Age: 52 Chief Financial Officer and Sr. VP Salary: $ 840.00K Bonus: $ 160.00K Mr. Aart Brouwer , Age: 68 Pres of International Salary: Bonus: $ 1.32M $ 0 Dr. Graham Burton MBBS, FRCP, Age: 58 Sr. VP Global Regulatory Affairs &Pharmacovigilance & Corp. Compliance Salary: $ 1.03M Bonus: $ 7.27M 1. Dow Jones Index - 30 Stocks on 11/12/2009:  Buy   93% or 28   Hold   7% or 2   Sell   0% or 0 stocks     2. World Markets - 72 Indexes on 11/11/2009:  Buy   63% or 44   Hold   21% or 15   Sell   16% or 11 indexes 3. Best Brands - 200 stocks on 11/12/2009:  Buy   76% or 152   Hold   17% or 33   Sell   7% or 14 stocks 4. Hot News - 200 stocks on 11/8/2009:  Buy   47% or 93   Hold   23% or 46   Sell   30% or 60 stocks 5. Big Movers - 200 stocks on 11/14/2009:  Buy   69% or 137   Hold   23% or 47   Sell   8% or 15 stocks 6. Top Hitters - 200 stocks on 11/11/2009:  Buy   77% or 153   Hold   15% or 31   Sell   8% or 15 stocks 7. S&P 500 Index - 500 Stocks on 7/21/2009:   Buy   68% or 341   Hold   21% or 106   Sell   11% or 53 stocks 8. S&P 400 Mid Cap - 400 Stocks on 7/21/2009:  Buy   73% or 292   Hold   15% or 61   Sell   12% or 47 stocks 9. S&P 600 Small Cap - 600 Stocks on 4/18/2009:  Buy   66% or 395   Hold   26% or 156   Sell   8% or 49 stocks 10. Nasdaq Telecom - 164 Stocks on 7/24/2009:  Buy   49% or 81   Hold   35% or 56   Sell   16% or 27 stocks 11. Nasdaq Computer - 440 Stocks on 7/22/2009:  Buy   60% or 263   Hold   26% or 115   Sell   14% or 62 stocks 12. Nasdaq Finance - 180 Stocks on 7/24/2009:  Buy   61% or 109   Hold   6% or 12   Sell   33% or 59 stocks 13. NYSE International - 100 Stocks on 7/21/2009:  Buy   58% or 58   Hold   34% or 34   Sell   8% or 8 stocks 14. Legg Mason Mutual - 346 Funds on 10/6/2009:  Buy   38% or 133   Hold   51% or 176   Sell   11% or 37 funds 15. T. Row Price Mutual - 161 Funds on 10/6/2009:  Buy   52% or 84   Hold   46% or 73   Sell   2% or 4 funds 16. London FTSE 100 - 94 Stocks on 4/1/2009:  Buy   20% or 19   Hold   50% or 47   Sell   30% or 28 stocks 17. Canada Toronto - 209 Stocks on 4/18/2009:  Buy   53% or 111   Hold   34% or 70   Sell   13% or 28 stocks                                              TOTAL RATINGS:   Buy   60% or 2493   Hold   27% or 1080   Sell   13% or 517 stocks 11/15/2009 Latest stock market news data for Celgene Corporati (NASDAQ:CELG) Stock on Sunday, November 15, 2009 Celgene Corporation to Present at the Lazard Capital Markets 6th Annual Healthcare Conference RTT News - Nov 13, 2009 SUMMIT, NJ --(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Lazard Capital Markets 6 th Annual Healthcare Conference on Tuesday, November 17, 2009 at ... The Life-and-Death Situation That Isn't Motley Fool - Nov 12, 2009 By Brian Orelli "This is literally a life-and-death issue that must be handled with great care." -- Celgene (Nasdaq: CELG) spokesman Brian Gill, as quoted in The Wall Street Journal. Was he ... Cramer Talks About HLF, BMY, PFE, CELG Benzinga - Nov 11, 2009 Jim Cramer has given a bullish call to Herbalife Ltd. (NYSE: HLF) as he feels that HLF is least expensive than its competitors and has also gained 148% over the last five years. Yesterday, HLF ... More Than 200 Abstracts Evaluating Celgene Products across a Range of Indications to Be Presented at the 51 st American Society of Hematology Meeting Business Wire - Nov 11, 2009 SUMMIT, NJ--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced that clinical investigators from leading hematology research centers around the world will present data from more ... Top Large Cap Biotech Picks From UBS Research The Wall Street Transcript - Nov 10, 2009 November 10, 2009 - The Wall Street Transcript has just published Biotechnology Report offering a timely review of the Biotechnology sector. This 70 page feature contains expert industry ... Blood Cancer Meeting Abstracts Released: BioBuzz TheStreet.com - Nov 10, 2009 By Adam Feuerstein 11/10/09 - 12:16 PM EST BOSTON, Mass. (TheStreet) -- Research abstracts for next month's American Society of Hematology annual meeting have been posted online. You can search ... Celgene in ASH Abstract Spotlight: BioBuzz TheStreet.com - Nov 10, 2009 By Adam Feuerstein 11/10/09 - 06:31 AM EST SUMMIT, NJ (TheStreet) -- Research abstracts for next month's annual meeting of the American Society of Hematology, or ASH, will be posted online Tuesday ... New Report Just Published Celgene Corporation - Detailed Product Pipeline Live-PR.com - Nov 9, 2009 (live-PR.com) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue. contain detailed information on pipelines by ... Celgene Corporation to Present at Two Upcoming Investor Conferences Business Wire - Nov 6, 2009 SUMMIT, NJ--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor ... Novavax, Inc. Beats Analyst Expectations; NVAX, LIFE, CELG Learning Markets - Nov 6, 2009 Analysts were expecting Novavax, Inc. (NVAX) [Chart - News - Analysis] to report earnings of $-0.09 for last quarter, but NVAX beat expectations with actual earnings of $-0.08---1 cent above the ... Cramer Talks About HLF, BMY, PFE, CELG Benzinga He also said that Pfizer Inc. (NYSE: PFE) gives investors a strong entry point since the stock is trading low after they reported their earnings. ... Herbalife Vs. Hedge FundsCNBC all 2 news articles » Celgene (CELG): Bet on biotech for 'offense and defense' BloggingStocks (blog) "I am recommending Celgene (NASDAQ: CELG) as part of an 'offense-defense' thesis," says Ian Wyatt. In Top Stock Insights, he reviews the leading ... Schaeffer's Daily Option Blog: Call Trading Skyrockets on Celgene (CELG)dBusinessNews Cincinnati (press release) all 6 news articles » Celgene: Buy on a Pullback Inside Futures From the technical perspective, Fitzpatrick believes Celgene (CELG) is a buy, but it could face some near term weakness. From reading the charts, this stock ... and more » SADIF Analytics releases new summary due diligence report for Celgene Corporation PR-Inside.com (Pressemitteilung) Ilhavo, Portugal – 09/11/2009 – SADIF Investment Analytics, announces a new summary due diligence report covering Celgene Corporation (CELG). ... and more » Earnings Preview (R, HOT, COF, CELG, RAI) - Stock Market TransWorldNews (press release) Celgene Corporation (NASDAQ:CELG) is estimated to report a profit of 54 cents a share in the third quarter, according to analysts surveyed by Thomson ... SuperGen-Glaxo Deal Couldn't Have Come at a Better Time Seeking Alpha (blog) With sales of its lead drug losing headway to rival Celgene's (CELG) Vidaza, striking a deal with GlaxoSmithKline (GSK) to collaborate on cancer drug ... and more » Pre-Market Round-Up for November 4, 2009 Sumfolio.com Celgene Corporation [[CELG]] – Shares of the biopharmaceutical company moved higher in pre-market hours after CNBC's Jim Cramer recommended the stock on his ... Celgene 3Q profit surges on cancer drug sales The Associated Press Shares of Celgene rose $2.24, or 4.1 percent, to $58.82 in morning trading. The stock has traded between $36.90 and $66.50 over the last 52 weeks. Celgene Corporation Q3 2009 Earnings Call TranscriptSeeking Alpha (blog) Celgene 3Q Beats Views; Raises 2009 EstimatesCapital.gr (press release) all 71 news articles » Celgene Corporation to Present at the Oppenheimer & Co. Inc. TransWorldNews (press release) SUMMIT, NJ-(CRWENEWSWIRE) Nov 2,2009 Celgene Corporation (NASDAQ: CELG - News) today announced its presentation at the Oppenheimer & Co. ... Investing in the Biotech Sector Investment U This conference addresses various cancers of the blood and among the presenters will be biotech heavyweight, Celgene (Nasdaq: CELG), ... and more » 11/15/2009 News from StockRing Blog about Celgene Corporati (NASDAQ:CELG) Stock on Sunday, November 15, 2009 12/7/2008 StockRing advise: SELL 33% or 163, HOLD 47% or 237, BUY ... CELG, HOLD - Celgene Corporation (NasdaqNM : CELG), Dec 5, 53.98, +1.20, +2.27%, 6958660. 90. CEPH, BUY - Cephalon, Inc. (NasdaqNM : CEPH), Dec 5, 76.59, +2.03, +2.72%, 1674210. 91. CF, SELL - CF Industries Holdings, Inc. ... 12/7/2008 stockring advise: sell 33% or 163, hold 47% or 237, buy ... celg, hold - celgene corporation (nasdaqnm : celg), dec 5, 53.98, +1.20, +2.27%, 6958660. 90. ceph, buy - cephalon, inc. (nasdaqnm : ceph), dec 5, 76.59, +2.03, +2.72%, 1674210. 91. cf, sell - cf industries holdings, inc. (nyse : cf) ... 12/25/2008 stockring advise: sell 35% or 176, hold 39% or 195, buy ... celg, hold - celgene corporation (nasdaqnm : celg), dec 24, 53.72, +0.24, +0.45%, 1330056. 90. ceph, buy - cephalon, inc. (nasdaqnm : ceph), dec 24, 76.60, +0.15, +0.20%, 295626. 91. cf, hold - cf industries holdings, inc. (nyse : cf) ... 11/22/2008 stockring buy-sell-hold ratings for s&p 500 stocks celg, sell - celgene corporation (nasdaqnm : celg), nov 20, 51.04, -4.72, -8.46%, 8197210. 90. ceph, hold - cephalon, inc. (nasdaqnm : ceph), nov 20, 70.32, -3.95, -5.32%, 2639410. 91. cf, sell - cf industries holdings, inc. (nyse : cf) ... 12/3/2008 stockring advise: sell 39.4% or 197, hold 50.4% or 252 ... celg, sell - celgene corporation (nasdaqnm : celg), 4:00pm, 52.60, +1.76, +3.46%, 4216565. 90. ceph, buy - cephalon, inc. (nasdaqnm : ceph), 4:00pm, 74.97, +2.74, +3.79%, 1933512. 91. cf, sell - cf industries holdings, inc. (nyse : cf) ... 12/7/2008 stockring advise: sell 33% or 163, hold 47% or 237, buy ... celg, hold - celgene corporation (nasdaqnm : celg), dec 5, 53.98, +1.20, +2.27%, 6958660. 90. ceph, buy - cephalon, inc. (nasdaqnm : ceph), dec 5, 76.59, +2.03, +2.72%, 1674210. 91. cf, sell - cf industries holdings, inc. (nyse : cf) ... 12/7/2008 stockring advise: sell 33% or 163, hold 47% or 237, buy ... celg, hold - celgene corporation (nasdaqnm : celg), dec 5, 53.98, +1.20, +2.27%, 6958660. 90. ceph, buy - cephalon, inc. (nasdaqnm : ceph), dec 5, 76.59, +2.03, +2.72%, 1674210. 91. cf, sell - cf industries holdings, inc. (nyse : cf) ... 12/3/2008 stockring advise: sell 39.4% or 197, hold 50.4% or 252 ... celg, sell - celgene corporation (nasdaqnm : celg), dec 3, 52.60, +1.76, +3.46%, 4216565. 90. ceph, buy - cephalon, inc. (nasdaqnm : ceph), dec 3, 74.97, +2.74, +3.79%, 1933512. 91. cf, sell - cf industries holdings, inc. (nyse : cf) ...    Abele John   Abrams George    Abrams Jonathan   Ackermann Josef   ACUSHNET   A.I.G.   AIG   Albright Madeleine   AMAZON.COM   AMERITRADE   Andelman David   Andreessen Marc   Angwin Julia   Anthony Jim   APAX PARTNERS   ARCH VENTURE PARTNERS   ARONSSON GROUP   Ashworth Paul   AT&T   AVON BOOKS   Bair Sheila   BANK OF AMERICA   BARCLAYS   Barton Rich   Bassett Angela   BEAR STEARNS   Begich Mark   Bell Bryon   Bennett Tony   Berke Barry   Bernanke Ben   BET   BETSEY JOHNSON   Biaggi Mario   Bierut Michael   Biondi Frank   Blankfein Lloyd   Blinder Alan   Bock Jeff   BOEING   Boncompagni Tatiana   Bond Adam   Bond Victoria   Born Brooksley   BOSTON SCIENTIFIC   BP   Brazinski Daniel   Breslin Jimmy   Brody Kenneth   Brown Greg   Burkle Ron   Burow Kristina   Burrough Bryan   Bush George W.   Callan Erin   CALLAWAY GOLF   CARLYLE GROUP    CASCADE INVESTMENT   Cassano Joseph   Dauman Philippe   De Niro Robert   Dickerson Paul   Dillon Harrison   DISNEY   Dodd Christopher   Donaldson William   Douglas Michael   Draghi Mario   DREAMWORKS SKG   DUTTON   Dykstra Lenny   Eisner Michael   ELECTRONIC ARTS   Emanuel Rahm   ENRON   ESL INVESTMENTS   Evans Robert   Falcone Philip   FANNIE MAE   FEDERATED DEPARTMENT   STORES   FINANCO   Flavin Jennifer   Fleckenstein Bill   Foreman George   Frank Barney   Frears Stephen   FREDDIE MAC   Freston Tom   Friedman Stephen   Fuld Dick   Furman Roy   Garavani Valentino   Gates Bill   Geffen David   Geithner Tim   GENERAL MOTORS   Gensler Gary   Gerdeman Fred   Gibson Charles   GLASSDOOR   GLG PARTNERS   GOLDMAN SACHS   Greenspan Alan   Greenspan Glenn   Grey Brad   Griffin Kathy   Griffin Ken   Grove Andy   HALSTON   HARBINGER CAPITAL   PARTNERS   Harrison Gilbert   Harrison Mya   HCR MANORCARE   HEWLETT-PACKARD   HILCO CONSUMER   CAPITAL   Hohman Robert   JEFFRIES & CO.   Jobs Steve   Johnson Magic   Johnson Robert   Jolie Angelina   Jordan Michael   JP MORGAN CHASE   Kaczynski Ted   Karan Donna   Kargman Jill   Karmazin Mel   Kashkari Neel   King Larry   Knowles Beyonce   KohlbergJerry   KopelmanArie   KopelsonAnne   KopelsonArnold   Korff Ira   Korff Kimberlee   Kurzman David   Lagrange Pierre   Lampert Eddie   Lansing Sherry   LEHMAN BROTHERS   LENDINGTREE   Levitt Arthur   Levy Leon   Liddy Ed   LINKEDIN   Little Edward   Loeb Allan   Lois George   LONG-TERM CAPITAL   MANAGEMENT   Lonski John   Lundgren Terry   MACYS   Madoff Bernie   Marcus Bernie   Marriott Bill   Maskin Eric   Mason Richard   MATTHEW WILLIAMSON   MAY DEPARTMENT   STORES   McCombs Red   McKinnon Mark   McLucas William   Meltzer Allan   MERRILL LYNCH   MGM   MICROSOFT   MIDWAY GAMES   Misner Jeff   Mitchell Andrea   Moglia Joe   Molinaro Sam   MOODYS INVESTORS   SERVICE   Moonves Leslie   Morgan Peter   MORGAN STANLEY   Moses Herb   MOTOROLA   Mozilo Angelo   Murdoch Rupert   Murphy Eddie   MYSPACE   Nader Ralph   Nardelli Bob   NATIONAL AMUSEMENTS   NEWS CORP.   Nicholas Pete   Nicklaus Tack   NICKLAUS DESIGN   NIKE   Norquist Grover   NRDC EQUITY PARTNERS   Obama Barack   ODYSSEY PARTNERS   Oman Brady   OPPENHEIMER & CO.   OReilly Bill   OReilly Tim   OVERTURE FILMS   Paese Michael   Palin Sarah   PALM   Pandit Vikram   PARAMOUNT PICTURES   Partnoy Frank   Pataki George   Paulson Henry   Paulson John   Preston Kelly   Purcell Philip   Pyle Jason   RBS GREENWICH CAPITAL   Reardon Roy   Redstone Brent   Redstone Eddie   Redstone Michael   Redstone Paula   Redstone Phyllis   Redstone Shari   Redstone Sumner   RELIANCE   RENAISSANCE TECHNOLOGIES   ROYAL DUTCH SHELL   Rubin Robert   SAC CAPITAL ADVISORS   SALTON   SAPPHIRE ENERGY   Schiff Stephen   Schrager Ian   Schumer Chuck   Schwartz Alan   Scott Lee   Shields Brooke   SHUTTERFLY   SIEMENS   Silverman Ben   Simons James   SIX APART   SOCIALIZR   SOLAZYME   Sorkin Aaron   Sorkin Andrew Ross   Soros George   Spielberg Steven   Spurlock Morgan   Stallone Sylvester   Stanley Stephen   Staubach Roger   Steel Robert   Steinberg Mark   Stern Andy   Stiglitz Joseph   ST. MARTINS PRESS   Stone Oliver   Sullivan Mark T.   Summers Lawrence   SUTTER HILL VENTURES   TACONIC CAPITAL PARTNERS   DESIGN TOMMY HILFIGER   Travolta John   Trump Ivanka   TSM CAPITAL   CENTURY FOX   AFRIKA   TYCO   UBS   UNITED ARTISTS   UNIVERSAL   VALENTINO FASHION   GROUP   VANTAGE   V AUSTRALIA   VENROCK ASSOCIATES   VIA COM   Volcker Paul   VONAGE   WACHOVIA   Wagner Paula   Wales Jimmy   Wallison Peter   WAL-MART   WarinJoseph   WARNER BROTHERS   WASHINGTON MUTUAL   Waters Maxine   Waxman Henry   Weinstein Bob   Weinstein Harvey   WEINSTEIN CO.   Weiser Stanley   Welch Jack   Welling Beau   Whitacre Ed   White Kevin   Whitehead John   Williams Brian   Wilson Victoria   WMS INDUSTRIES   Wolfson Jonathan    Copyright © 2009 StockRing.com. All rights reserved. Subscriber Agreement   Privacy Agreement   Stocks   MutualFunds Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither StockRing.com nor its partners shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the StockRing site, a user agrees not to redistribute the information found therein.

Buy from S&P 500:
Akamai - AKAM
Amazon.com - AMZN
Big Lots - BIG


Sell from S&P 500:
Alcoa - AA
Autodesk - ADSK
Aflac - AFL


Buy from S&P 400 MidCap:
Carmax - KMX
99c Stores - NDN
Netflix - NFLX


Sell from S&P 400 MidCap:
Timken - TKR
Trinity - TRN
Aflac - AFL


Buy from S&P 600 SmallCap:
Coinstar - CSTR
Holly - HOC
Maximus - MMS


Sell from S&P 600 SmallCap:
Barnes - B
Cascade - CAE
Brightpoint - CELL


Buy from Nasdaq 100:
Baidu.com - BIDU
Verisign - VRSN
Yahoo - YHOO


Sell from Nasdaq 100:
Adobe - ADBE
Amgen - AMGN
Costco - COST


Buy from Nasdaq Telecom:
Adtran - ADTN
CalAmp - CAMP
KongZhong - KONG


Sell from Nasdaq Telecom:
iBasis - IBAS
Interphase - INPH
RCN Corp - RCNI


Buy from Nasdaq Biotech:
Eurand - EURX
Illumina - ILMN
Trimeris - TRMS


Sell from Nasdaq Biotech:
Antigenics - AGEN
Celera - CRA
Incyte - INCY


Buy from Nasdaq Computer:
eLoyalty - ELOY
LogicVision - LGVN
Macrovision - MVSN


Sell from Nasdaq Computer:
Amtech - ASYS
Bsquare - BSQR
Corel - CREL


Buy from Nasdaq Finance:
Elbit - EMITF
Chardan - CACA
Tree.com - TREE


Sell from Nasdaq Finance:
BancFirst - BANF
FirstMerit - FMER
Advanta - ADVNA